California-based Profluent Bio developed a system capable of creating a range of bespoke cures for disease by developing molecules that have never existed in nature.
DailyMail.com spoke to Ali Madani, CEO of Profluent Bio, who said the AI-made gene editors have been tested in human cells, which demonstrated high levels of functionality while not editing unintended sites in the DNA.
The AI was trained on a database of 5.1 million CRISPR-associated (Cas) proteins, allowing it to create potential molecules that could be used in gene editing.
The system then narrowed down the results to four million sequences, allowing it to identify the gene editor the team named OpenCRISPR-1.
Experiments showed OpenCRISPR-1 performed as well as Cas proteins, but it also reduced the impact on off-target sites by 95 percent.
Share this article
‘Attempting to edit human DNA with an AI-designed biological system was a scientific moonshot,’ Madani said.
‘The molecules do not exist in nature like previous technologies in gene editing such as CRISPR.’
